arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Digital Health Summit Europe 2016

Innovation through collaboration: Bringing disruption to the patient

London |
Speakers include:
Dr Priya Agrawal

Dr Priya Agrawal

MSD for Mothers

The Rt Hon George Freeman

The Rt Hon George Freeman

UK Government

Dr Karl  Pall

Dr Karl Pall

Google

Overview

The FT Digital Health Summit Europe returned to London this year and brought delegates a top-level speaker roster and agenda. Formulated to give attendees the latest insights into the  the most pressing issues to date - putting the patient first, cyber security threats in healthcare and interoperability in existing IT infrastructures. Entitled ​ ‘​Innovation through collaboration: Bringing disruption to the patient’, the Summit gathered an audience of C-­suite executives and co-­founders from the full range of healthcare players.

New stakeholders continue to push the boundaries of health and technology intersections while multinational corporations continue to invest more and more into the promise of digital health. But to be expected, as digital health practices become more widely used regulations and safety procedures increase in number, posing yet further challenges for the acceptance of digital healthcare.

Brandcast Media joined us at the event this year and did a number of interviews with our speakers. You can view these here >>

fallback
fallback Add to my Calendar 06/16/2016 08:00:0006/16/2016 20:00:00trueFT Digital Health Summit Europe 2016The FT Digital Health Summit Europe returned to London this year and brought delegates a top-level speaker roster and agenda. Formulated to give attendees the latest insights into the  the most pressing issues to date - putting the patient first, cyber security threats in healthcare and interoperability in existing IT infrastructures. Entitled ​ ‘​Innovation through collaboration: Bringing disruption to the patient’, the Summit gathered an audience of C-­suite executives and co-­founders from the full range of healthcare players.New stakeholders continue to push the boundaries of health and technology intersections while multinational corporations continue to invest more and more into the promise of digital health. But to be expected, as digital health practices become more widely used regulations and safety procedures increase in number, posing yet further challenges for the acceptance of digital healthcare.Brandcast Media joined us at the event this year and did a number of interviews with our speakers. You can view these here >>FT-Digital-Health-Summit-Europe-20162e88f51089fbca99a5a2cfc9cfac9a79MM/DD/YYYY

Brochure Download

Brochure Download

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

Data Protection

By submitting this form you consent to being contacted by FT Live about this event by phone and email.

Thank you for submitting your details. Please download the event brochure.

Untitled Block

"Excellent investment of time. Brought the right people together to address the challenging questions"
- Jessica Federer, Chief Digital Officer, Bayer

"Excellent opportunity to learn and network"
- Klaus Dugi, Senior Vice President Medicine and Chief Medical Officer, Boehringer Ingelheim

"A great opportunity to make new connections"
- Pascale Witz, Executive Vice President, Global Divisions and Strategic Development, Sanofi

fallback

Follow us on Twitter

Twitter 2

More

Speakers (29)

Dr Priya Agrawal

Dr Priya Agrawal

Executive Director
MSD for Mothers

Priya Agrawal is Executive Director of MSD for Mothers — Merck's 500 million dollar, ten-year commitment to ending preventable maternal mortality. She is an Obstetrician and Gynecologist and global women's health expert.

Dr Agrawal previously served as Director of Research and Development for the Women and Health Initiative at the Harvard School of Public Health, where she led the implementation research agenda and supported the development and evaluation of healthcare innovations. She continues as Visiting Scientist at the Harvard School of Public Health. She was Obstetric Lead on the World Health Organization's Safe Childbirth Checklist Program in India, working closely with Dr Atul Gawande and Medical Director of Jacaranda Health, Kenya — a social enterprise focused on delivering high quality, affordable maternal and child health services in the slums of Nairobi — leveraging process innovation. She started her public health work in Nigeria with the introduction of simpler, one-stop shop cervical cancer screening programs delivered by nurses. Dr Agrawal has worked and travelled in more than 45 countries using the introduction of simple and sustainable innovations to improve the health outcomes for underserved women and their families.

After receiving her degrees in medicine from the University of Cambridge and Oxford, she graduated with a master's from the Harvard School of Public Health on a Fulbright Scholarship, and is finishing her Ph.D. at the London School of Hygiene and Tropical Medicine. In 2012, Dr Agrawal's contributions to global women's health were recognized with the Harvard School of Public Health Alumni Award for Public Health Professionals.

She is a strong believer in iterative design and frugal innovation to drive the quality and value agenda and 'paying-it-forward' by mentoring the professionals of the future.

The Rt Hon George Freeman

The Rt Hon George Freeman

Minister for Life Sciences
UK Government

George Freeman was elected to Parliament in 2010 after a 15 year career across the life sciences sector, in particular working with hospitals, clinical researchers, patient groups, and biomedical research companies to pioneer novel healthcare innovations.

Following his election to Parliament in 2010, he served as PPS to the Minister of State for Climate Change. He was appointed Government Adviser on Life Sciences in July 2011, working closely with the Department of Health and coordinating the Government’s Life Science and Innovation, Health and Wealth Strategies (2011), and the Agri-Tech Industrial Strategy (2013). Following that, Mr Freeman was appointed to the post of Prime Minister’s UK Trade Envoy.

In July 2014, he was appointed as Minister for Life Sciences, a Parliamentary Under-Secretary of State at the Department of Health and Department of Business, Innovation and Skills. His mission is to make the UK the best place in the world to discover and develop 21st Century healthcare innovations.

Dr Karl  Pall

Dr Karl Pall

Director of Brand Solutions DACH (Germany, Austria and Switzerland)
Google

Karl Pall was born and studied in Vienna. He has a PhD in Sc of Communication and Economics. Previously, Dr Pall worked for international advertising agencies Grey, D’Arcy and JWT in Hamburg, London and Vienna. In 1992 Dr Pall then moved to an agency in Tokyo, before moving back to Vienna to become the co-founder of his own agency.

From there Dr Pall moved to Coca-Cola as the Marketing and Communication Director for several European countries. Moving into 2005, he then co-founded and became Managing director of 12snap Mobile Marketing. In September 2006 he started to run the business for Google in Austria and became Country Manager.

In September 2011 he then moved to Toronto to become Head of Industry at Google Canada. Dr Pall then became Managing Director of Brand Solutions at Google Canada and in September 2014 he moved to Hamburg and became Director for Google’s Health Branding business.

Dan  Taylor

Dan Taylor

Programme Head of Cybersecurity
Health and Social Care Information Centre

Dan Taylor is the Programme Head for the Cyber Security Programme (CSP) and current interim head for HSCIC Security Operations. The CSP is delivering a number of projects to build a cyber security defence in depth for HSCIC and the systems that it delivers. A number of projects will also strengthen the cyber defences of health and social care through enhancing, people, process and technology. One of the projects will deliver a CareCERT service, which supports the health and social care system to enhance its cyber security preparedness, and consume warnings and advisories, in order to respond effectively to potential threats.

For the last 10 years Mr Taylor has been working in healthcare, having worked in every tier of the NHS prior to moving to Connecting for Health and then HSCIC. Within the NHS, he worked in various postings across the country, in a number of management posts, before working at a national level delivering change through a number of national programmes.

Dr Ali  Parsa

Dr Ali Parsa

CEO
Babylon

Dr Ali Parsa is a healthcare entrepreneur, and the founder and CEO of babylon.

Babylon is the UK’s leading digital healthcare service. Its mission is to make healthcare more accessible and affordable to people around the world by combining first class technology with the best clinical expertise. Launched in February 2015, babylon enables users to book a video consultation with a GP in minutes, or text in a question or photo to receive a free answer from a clinician for simpler queries. It has already expanded its service into Europe and is planning to launch in Africa in 2016.

Before founding babylon, Dr Parsa built Circle in a five year period to become Europe's largest partnership of clinicians, with some £200m of annualised revenue, near 3,000 employees and a successful IPO. Prior to Circle, he was an investment banker with Goldman Sachs. He was the recipient of the Royal Award for the Young Entrepreneur of the year in 1993 for founding his first business, V&G, and the healthcare Entrepreneurial Achievement in 2010. Dr Parsa was named by the Times among the 100 global people to watch in 2012 and by HSJ as among the 50 most influential people in UK healthcare.

Dr Matt Jameson Evans

Dr Matt Jameson Evans

Co-founder and Chief Medical Officer
HealthUnlocked

Matt Jameson Evans is Co­-founder of HealthUnlocked and previously an orthopaedic surgeon in the NHS.

He is a fellow on the NHS Innovation Accelerator initiative launched in 2015 as part of Simon Stevens’ Five Year Forward View plan.

With over 600 health­specific communities, 3 million monthly users, and 400,000 member/ bloggers, HealthUnlocked is the leading platform for patient peer support and self­care. At its heart is an artificial intelligence designed to learn the needs of users and signpost them to recommended content or services. Increasingly HealthUnlocked is being used as a personal care planning and signposting tool in the NHS and is currently being used in 85 NHS Trusts.

Adam  Plich

Adam Plich

VP, Head of Pricing & Market Access Europe
Teva Pharmaceuticals

A pharmacist by training, Adam Plich has 10 years of experience in pricing, market access and health economics in the pharmaceutical industry. Since 2012 he has been leading the pricing and market access team and activities at TEVA Europe for specialty, biosimilar and generic medicines. He is also a chair of the Health Technology Assessment (HTA) working group at the European Generics Association (EGA) where – together with other companies – he develops and advocates for the tailored use of HTA in the assessment of the value added medicines. Medicines that are based on known molecules which deliver considerable improvements for patients, payers and/or healthcare professionals. Mr Plich is a frequent conference speaker and a lecturer of pricing and market access at the post­graduate studies at the University of Aix Marseille, France and the University of Economics Poznan, Poland. He has authored and contributed to numerous health economic and health policy posters and publications.

Mark Duman

Mark Duman

Non-Executive Director, Patient Information Forum
& Director, Intelesant

Mark Duman is a rare blend of clinician, management consultant and patient advocate.  He works with organisations to help them realise the full benefit of their services and products, especially through the often untapped potential of patients and the public.

At the King’s Fund he promoted shared decision making, founded the Ask About Medicines campaign and authored ‘Producing Patient Information’. In the BBC he developed a range of behavioural change interventions to improve people’s health and lifestyle. Following roles in publishing and telecoms, his clients include AstraZeneca, Cancer Research UK, Care Quality Commission, Department of Health, Microsoft, NHS England, Scholl, Tunstall Group and UCB Pharma.

Advisory roles have included the Ministerial Industry Strategy Group on Medicines Access, NHS Alliance People Powered Innovation Group and NHS England’s Insight Strategy Group. He is a Non Executive Director of the Patient Information Forum, and a full time Director at Monmouth Partners Ltd. Mr Duman is a long term condition patient (and advocate) who lives in Manchester, England.

James Wise

James Wise

Partner
Balderton Capital

James Wise joined Balderton in 2013. Since then, he has led Balderton's investments in a number of sectors and geographies, with a specific focus on healthtech, manufacturing, mobile productivity, developer tools and financial accessibility. He sits as a board member and observer for multiple portfolio companies.

Prior to joining Balderton, Mr Wise helped launch a charity, the Social Business Trust, one of the UK's first social venture funds, providing support and capital to a portfolio of start-ups with a special focus on the education, healthcare and financial sectors. He has previously worked with entrepreneurs and businesses in Europe, the Middle East and Africa, with Atomico Ventures, the Guardian Media Group and as a consultant with McKinsey & Company.

As well as his professional experience, Mr Wise has worked as an adviser to a number of start­ups and social enterprises, and in 2011 as a Specialist Adviser to British Parliament. He has an MA in Politics, Philosophy and Economics from Oxford University where he occasionally lectures on aspects of responsible capitalism and the social impact of technology.

Jamie  Wilson

Jamie Wilson

Founder and CEO
HomeTouch

Dr Jamie Wilson is the founder and CEO of HomeTouch, an online marketplace that makes it easy for families to find quality, affordable home care. He is also a physician and memory specialist with 10 years' experience working across the NHS.

Dr Wilson has product managed digital healthcare products and had senior roles across the healthcare value chain including the BMJ Group, Novartis and a neurotech start­up based in Silicon Valley.

He has a medical degree from Leeds University Medical School, is a member of the Royal College of Psychiatrists, and received an MBA from London Business School and UC Berkeley.

HomeTouch has been funded by BUPA, Guys and St Thomas’s Charity, the Nominet Trust and, most recently, Passion Capital.

Dr Sophie Chung

Dr Sophie Chung

CEO and Founder
Junomedical

Sophie Chung is currently the CEO and Founder of Junomedical, a digital medical travel hub that is providing patients around the world access to affordable healthcare treatments. Prior to founding Junomedical in 2015, she served as the Director of Healthcare Strategy at Zocdoc, a healthcare technology startup focused on doctor discovery and appointment booking. Dr Chung acted lead on healthcare strategy and formulated product development as well as strategic business partnerships for the company. She was also a project manager for McKinsey & Company’s Healthcare Practice in Germany where she worked with government, hospital, health insurance and pharmaceutical industry clients.

After earning her MD degree from Medical University of Vienna in 2008, Dr Chung gained first-hand experience in treating patients as a doctor in Australia tackling the complex issues involved in providing people with access to healthcare whilst working at an NGO in Cambodia. She has completed and presented academic stem cell research, as well as given keynote presentations on academic research and consumerism in healthcare. These experiences have ignited her passion to provide everyone with access to healthcare regardless of where they live. She believes that there is an opportunity to fundamentally transform how patients access and experience healthcare. By founding Junomedical, she is on a mission to connect patients with the very best accredited doctors and hospitals so that they can receive high-quality treatment at an affordable price.

Unity Stoakes

Unity Stoakes

Co-founder and President
StartUp Health

Unity Stoakes is on a mission to reinvent health and wellness by leveraging the power of networked entrepreneurs, innovation, technology, data, design, collaboration and community. Unity is the Co-founder and President of StartUp Health, which is organizing and supporting a global army of Health Transformers. With more than 350 Healthcare Transformers and 200 companies, StartUp Health spans more than a dozen countries and 60 cities.
Unity has been a technology entrepreneur since the mid-nineties, previously co-founding OrganizedWisdom and helping build The Privacy Council, Middleberg Interactive and Webstakes.com/Promotions.com, which he helped take public on NASDAQ with his business partner of 20 years, Steven Krein. 

Unity is a contributing writer for Forbes and has been a guest on Bloomberg TV, CNBC and USA Today. He is also the host of StartUp Health NOW, a weekly web show on the entrepreneurs and changemakers reimagining health.
Unity is a founding member of the Society of Participatory Medicine and on the AARP Innovation @50+ Advisory Board, the SXSW Accelerator Advisory Board and Care Innovations Advisory Board. He received his BA in Communications and Political Science from Boston University.

Chris Moore

Chris Moore

Partner, EMEIA Advisory
EY

Chris Moore is the Lead Partner for Life Sciences Advisory in EY in EMEIA focused on providing digital and advanced analytics support through major transformation programmes to clients throughout Europe.

He is the lead partner for Life Sciences Advisory in EY in EMEIA focused on providing strategy and major transformation support to clients throughout Europe. Mr Moore works with large and small organisations around a number of engagements ranging from business strategy to systems implementation. He has worked across the Life Sciences value chain globally for the past 25 years on projects as diverse as the first document management systems in the industry through to clinical re­-design programmes.

He has worked with clients on first of a kind programme to enable analytics to model biological outcomes, assist in better diagnosis, improve drug discovery and improve medicine marketing by outcomes.

His career has seen him build and run the European, Alps and US West Coast Life Sciences practices for IBM, as well as building content management and emerging technology teams for IBM, PwC, Coopers & Lybrand and Kinesis.

Mr Moore is a key contributor towards numerous thought leadership papers and a regular speaker at industry events and forums.

Charles Lowe

Charles Lowe

Managing Director, Digital Health and Care Alliance /
Past President - Telemedicine Section, Royal Society of Medicine

Charles Lowe has a background in finance and IT. In 2004 he established a telecare programme at LB Newham, at one time the UK’s largest, and won Department of Health Whole System Demonstrator (WSD) funding to extend  it to telehealth. In 2008 he joined Telehealth Solutions (now Medvivo), driving the development and sale of telehealth services. In 2011 he established telecare and telehealth programmes in Surrey, leading to one of the largest successful UK telehealth deployments.

His recent work has centred on mHealth apps, including publishing a detailed compendium of the regulations affecting them, being on the drafting group of the EU Code of Conduct on Privacy, and drafting the voluntary EU mHealth app assessment guidelines for the EC. Mr Lowe was the only digital health expert named in the recent OLS-published Accelerated Access Review. He is Managing Director of the Digital Health & Care Alliance (DHACA), an Expert Reviewer for the EC, a Contributing Editor to www.telecareaware.com, organiser of the London Health Technology Forum, a Special Adviser to the CQC, and immediate Past President of the Royal Society of Medicine’s Telemedicine and eHealth Section. He chairs Citizens Online, the digital inclusion charity.

Pablo  Graiver

Pablo Graiver

CEO
TrialReach.

Pablo Gravier is the founder and CEO of TrialReach. Since 2009, under his leadership, the company has raised almost US$20m in venture capital and grown to become a leading player within the digital health sector, empowering thousands of patients worldwide to discover and access potential new treatment options.

Mr Gravier is a seasoned entrepreneur and manager of internet companies. He’s been building high ­scale businesses in online retail, travel, mobile, media, and now health sectors since the late 90s, including firms such as NetJuice, DondeComprar.com, Kelkoo.com (acquired by Yahoo!), Kayak.com (acquired by Priceline), and ValueClick (acquired by Conversant).

He has spoken about technology, healthcare, and innovation at Harvard Medical School and various international digital health events. He was recently included in the “100 Club” by SVC2UK and the “Ones To Watch” list by The Sunday Times’ Tech Track 100. In addition, he's been featured in the Financial Times, Forbes, TechCrunch, Re/code, and more.

Mr Gravier graduated with a Bachelor in Business Studies at Universidad Antonio de Nebrija and studied Biology at the Universidad Autonoma de Madrid.

Sophie Bostock

Sophie Bostock

Sleep Evangelist
Big Health

Sophie Bostock is a Sleep Evangelist at Big Health, a pioneering digital medicine company. Big Health creates automated behavioural medicine programs fueled by tracked data. Big Health’s first product, Sleepio, is clinically proven to help overcome even long term poor sleep. Dr Bostock has worked with healthcare providers and large employers to test the impact of Sleepio delivered at scale. She will share highlights from new research in the workplace showing that Sleepio boosts both sleep and productivity. Mental healthcare providers are now using Sleepio to help reduce anxiety and depression.

Before joining Big Health, she completed a PhD in Health Psychology at UCL. She explored the links between work stress, happiness and health. This led to an interest in sleep, and the role of technology for facilitating population level behaviour change. When she’s not sleeping, or talking about it, Dr Bostock also teaches Public Health at the University of Southampton.

Richard  Corbridge

Richard Corbridge

Chief Information Officer
eHealth Ireland

Richard Corbridge is the Chief Information Officer for the Health Service Executive in Ireland and Chief Officer of eHealth Ireland. He has specialised in IT strategy development, procurement, implementation and the assurance of benefit release across national and local health care arenas in the UK and across the globe for more than fifteen years, achieving significant impact in both areas. 

In these roles, Mr Corbridge has delivered a wide range of systems and process to aid with the provision of integrated health care and clinical research. He took up the dual role within Ireland at the beginning of 2015. eHealth Ireland is a new organisation responsible for the delivery of an eHealth Eco­System for Ireland that will facilitate the health informatics innovation delivery country wide and is currently focused on the delivery of the published Knowledge and Information plan.

In 2015 he was listed as the 5th most influential CIO in Europe by CIO magazine and in the top 10 most social CIOs in the world.

Augustine  Amusu

Augustine Amusu

Head of IT Programmes
HCA Hospitals

Augustine Amusu has been with HCA Healthcare UK for 8 years, where he is involving in setting technology strategy, working closely with hospital leadership and diverse stakeholder groups on value creation, user experience; leading to optimal outcomes for  patient.He has led multiple greenfield projects and transformation initiatives for the group, some of which include: The Shard Outpatient facility, Manchester Institute of Health and Performance (MIHP), physician portal, digital intensive care unit, capacity management, vital signs, integrated EMR, infrastructure etc.Mr Amusu holds a BSc in Systems Engineering and Management (1st Class) from Richmond, The American International University in London and an MBA from Imperial College Business School, London. 

Alexandra Pelletier

Alexandra Pelletier

Presidential Innovation Fellow
The White House

Alexandra Pelletier has over 15 years of experience aligning business strategy with the development of digital products and services. She is currently a Presidential Innovation Fellow, a program created by the White House in 2012. 

Previously, Ms. Pelletier built digital health innovation programs at adult and pediatric Harvard Medical School affiliated academic medical centers. She served as the first Director of Digital Innovation at Boston Children’s Hospital. At Partners' Center for Connected Health, she was instrumental in launching the first ever connected health platform using a range of digital health technologies to transform the traditional provider-based, in-office care delivery approach. She expanded these programs to create industry partnerships and commercialize internally developed products. The successes led to the broader strategic vision for these academic medical centers to prepare for the future of care delivery. 

Ms. Pelletier was a consultant at IBM Global Services and Deloitte working across industries. She is passionate about leading talented teams to develop technologies that deliver a positive impact for people.

Pēteris  Zilgalvis

Pēteris Zilgalvis

Head of Unit eHealth and Well Being
DG CONNECT European Commission

Pēteris Zilgalvis is the Head of Unit for eHealth and Well Being in DG CONNECT. He was the Visiting EU Fellow at St. Antony's College, University of Oxford for 2013­14, where he is also an Associate of the Political Economy of Financial Markets Programme. Previously, he was Head of the Governance and Ethics Unit, Directorate Science, Economy and Society at DG Research within the European Commission.

From 1997 to 2005, he was Deputy Head of the Bioethics Department of the Council of Europe, in its Directorate General of Legal Affairs. In addition, he has held various positions in the Latvian civil service within the Ministry of Foreign Affairs and Ministry of Environment. He was Senior Environmental Law Advisor to the World Bank/Russian Federation Environmental Management Project and was Regional Environmental Specialist for the Baltic Countries at the World Bank. 

Pēteris studied political science (cum laude) at the University of California, Los Angeles. At the Law Centre of the University of Southern California he obtained his JD (Doctor of Jurisprudence) and received the Darling Foundation academic scholarship. He completed the High Potentials leadership Programme at Harvard Business School. He is a member of the California State Bar. He has published over 30 publications on bioethics, economics and finance, innovation law and policy, European and environmental law in English, Latvian, and French. A recent publication includes “The Need for an Innovation Principle in Regulatory Impact Assessment: The Case of Finance and Innovation in Europe” in Policy and Internet.

Sarah  Haywood

Sarah Haywood

CEO
MedCity

Sarah Haywood became Chief Operating Officer of MedCity in October 2014, after fulfilling the role in an acting capacity since its launch in April 2014 alongside her position as Head of Life Sciences at London & Partners, and was appointed CEO in December 2015.

She is a graduate of the NHS Management Training Scheme in Wales and started her career in the NHS, working in a number of Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as Head of Operations for a neuroscience drug discovery unit.

From there, she joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. In January 2014 she joined London & Partners where she worked with Dr Eliot Forster to establish MedCity.

Ms Haywood has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Chartered Management Institute.

Martin  Kelly

Martin Kelly

Co­founder and CEO
HealthXL

Martin Kelly is the Co-­founder and CEO of HealthXL, a global platform for digital health innovation. The HealthXL platform supports 22 of the leading global healthcare firms who use the community to engage patients, entrepreneurs and investors around specific challenges.

Mr Kelly was previously a partner with IBM Venture Capital and awarded Global Corporate Venturing Personality of the Year in 2012. He has served as an advisor to Innovation Fund Ireland and the Science Gallery (inc. co­curator of Hack the City).

He is passionate about entrepreneurship and collaboration to solve our biggest challenges. He has a BSc in Information Systems from Trinity College and an MBA from University College Dublin.

Andy	 Kinnear

Andy Kinnear

Director of Digital Transformation
NHS South, Central and West Commissioning Support Unit

Andy Kinnear is an experienced Chief Information Officer (CIO) in his 25th year with the NHS. He has a successful track record of delivering information and technology strategy and solutions and a wholehearted commitment to improving the health and care system.

He has three roles. Substantively he is the Director of Digital transformation for South, Central and West CSU looking after the delivery of 200+ digital projects to NHS organisations across the South of England. In addition, he is also the Programme Director for Connecting Care ­ the Bristol, North Somerset and South Gloucestershire interoperability programme. Connecting Care is a partnership of 17 organisations in the West Country and has successfully created a single shared record combining data from GP Practices, Community Services, Local Authorities, Acute Hospitals and Out­of­Hours services. Connecting Care is recognised as one of the leading integrated digital care record (IDCR) programmes in the country.

In his third role, Mr Kinnear is also currently seconded to the Health and Social Care Information Centre (HSCIC) advising them on Health and Social Care Integration and is working closely with national health and care agencies on the development of the integration strategy. This roadmap will seek to outline the stages to deliver fully integrated care records, an ambition laid out in the Five Year Forward View and Personalised Health and Care 2020.

He is a keen advocate of the benefits an integrated care records can bring at the point of care, but moreover understands and actively promotes the secondary use of this data to support the improvement of services.

Mr Kinnear is a member of the national CIO network and works closely with colleagues on the development of the informatics profession within health and social care. He is an experienced public speaker and routinely presents at national conferences on health and care information topics.

Christoph  Ruedig

Christoph Ruedig

Partner
Albion Ventures

Christoph Ruedig is a partner at Albion Ventures and focuses on investments in healthcare and renewables. He initially practised as a radiologist, before working at Bain & Company. He then joined 3i working for their Healthcare Venture Capital arm. He has also worked for General Electric's healthcare division, where he was responsible for mergers and acquisitions in the medical technology and healthcare IT sectors. He holds a degree in medicine from Ludwig-Maximilians University, Munich and an MBA from INSEAD.

Wilhelm Muehlhausen

Wilhelm Muehlhausen

Head of Innovation
ICON

Wilhelm Muehlhausen has been involved in clinical research for more than 20 years and held positions in Data Management, Clinical Research Operations and Project Management, Business Development and Product Management including Innovation. In 2015 he was selected by PharmaVoice magazine as one of the Top 100 most inspiring people in the Life Sciences industry. During his career he always worked on the service provider side and developed new products and services for CROs and technology providers. Mr Muehlhausen represented the ePRO vendors as the inaugural Vice Chair of the ePRO consortium and oversaw the development of important guidelines regarding the development and migrations of questionnaires from paper to electronic formats.

His team at ICON researched various aspects of migration issues and published several posters and articles to share these findings. These publications will support the industry in developing new approaches to eCOA, specifically with BYOD in mind. ICON is currently involved in several research projects to support BYOD models in eCOA and other areas in our industry.

Guy Yeoman

Guy Yeoman

Vice President, Patient Centricity
AstraZeneca

Guy Yeoman qualified in medicine and worked in the NHS in the 1990’s.  He spent five years at GlaxoSmithKline in clinical development, medical affairs and project management before moving to develop UK medical affairs and market access for a French company. He has spent the last seven years with AstraZeneca, initially as the UK Medical Director before moving to Asia to build an integrated medical affairs capability across Asia Pacific.  More recently Dr Yeoman established a new global Medical Evidence Centre focussed on delivering integrated evidence, external science and publications. He is now Vice President, Patient Centricity at AstraZeneca where his team focuses on the fast and efficient delivery of patient centric medicines and services. 

Tom O'Leary

Tom O'Leary

Chief Information Officer
ICON

Tom O’Leary is ICON's Chief Information Officer. Previous roles at ICON have included President of ICON Central Laboratories (2010-2013) and Global Head of Data Management (2006 – 2009). He is a Board Member of IPPOSI (Irish Platform for Patients’ Organisation Science and Industry). IPPOSI promotes optimal health for the public at large including the prevention or relief of sickness and disease, by providing a forum to inform and support the advancement of health research for the development of therapies and cures for unmet medical needs.

Prior to joining ICON, Mr O’Leary worked for SmithKline Beecham and later GlaxoSmithKline and held positions in Data Management, Project Management and Resource Management. He is a graduate of Kingston University in Surrey and a Member of the Royal Society of Chemistry. He holds a Degree in Medicinal Chemistry and a Masters in Data Management.

Fabrice  Naftalski

Fabrice Naftalski

Head of Digital and Data Privacy Law Practice, EMEIA
EY

Fabrice Naftalski is EY’s EMEIA Head of Digital and Data Privacy Law practice. He is an attorney with 20 years’ experience and has worked with the French law firm Poitrinal & Associés and then within the e-business/ IPIT group of Andersen Legal (Archibald), now part of EY.He is a graduate of the English and North American Business Law University, Panthéon/Sorbonne (DEA) and holds the Paris Bar specialty in Information Technology & Telecom law.

Mr Naftalski has experience working on contractual and regulatory projects in connection with the use of Information Technology (data protection and privacy law, IT contracts such as outsourcing agreement, software implementation agreements, internet law and e-commerce, etc.) and also on transactions dealing with intangibles (trademarks, patents, know-how, database, software, etc.).

He assists clients at French and European levels in data protection law compliance programs and tools covering inter-alia inventory of data files, compliance audit and privacy impact assessment, drafting of notifications to the Data Protection regulators, personal data management procedures (including Binding Corporate Rules and other tools to secure transfers), relations with national data protection national regulators, retention policies, whistle blowing policies and codes of conduct.

Scott Steedman

Scott Steedman

Director of Standards,
BSI Group

Scott Steedman is Director of Standards at BSI where he is responsible for the UK National Standards Body (NSB), representing UK interests in business standards and advising industry and government on the role of standardisation and knowledge transfer in innovation and economic growth. BSI maintains the infrastructure for all UK industry sectors to participate in the work of the international and European standards organisations. He has developed bilateral relations with countries around the world to align interests and create opportunities for cooperation between industry experts on market relevant issues.

Mr Steedman is a keen advocate for the value of voluntary consensus standards as best practice knowledge for business and industry, accelerating innovation, productivity and growth. He is very active in new fields of emerging technology, smart cities and the digital economy and is developing the role of standards in the service sector and in governance and leadership. He is committed to increasing public awareness of the role of standards in international trade and economic growth.

A civil engineer by background, he was a Fellow at Cambridge University before spending twenty years working in industry for consulting and contracting companies on major infrastructure and building projects around the world. He is a former Vice President of the Royal Academy of Engineering and of the Institution of Civil Engineers.

fallback

Chaired By (2)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Chris Moore

Chris Moore

Partner, EMEIA Advisory
EY

Chris Moore is the Lead Partner for Life Sciences Advisory in EY in EMEIA focused on providing digital and advanced analytics support through major transformation programmes to clients throughout Europe.

He is the lead partner for Life Sciences Advisory in EY in EMEIA focused on providing strategy and major transformation support to clients throughout Europe. Mr Moore works with large and small organisations around a number of engagements ranging from business strategy to systems implementation. He has worked across the Life Sciences value chain globally for the past 25 years on projects as diverse as the first document management systems in the industry through to clinical re­-design programmes.

He has worked with clients on first of a kind programme to enable analytics to model biological outcomes, assist in better diagnosis, improve drug discovery and improve medicine marketing by outcomes.

His career has seen him build and run the European, Alps and US West Coast Life Sciences practices for IBM, as well as building content management and emerging technology teams for IBM, PwC, Coopers & Lybrand and Kinesis.

Mr Moore is a key contributor towards numerous thought leadership papers and a regular speaker at industry events and forums.

Agenda - 16th Jun

  • 8:00am
    Registration and welcome refreshments
  • 9:00am
    Welcome remarks from the chair

    David Crow, Senior US Business Correspondent, Financial Times

    Section 1 – The patient focus

  • 9:05am
    Opening keynote: Empowering the patient

    Over the past 12 months the digital health industry has seen a dramatic increase in deals, partnerships and investment. This increase in momentum has resulted in wider access to information and awareness of digital health for patients and consumers alike. How will this change the delivery of healthcare as we know it? By greater empowering patients through digital health innovations, what are the opportunities and challenges that lie ahead?

    The Rt Hon George Freeman, Minister for Life Sciences, UK Government

  • 9:30am
    Bridging the intersection between health and digital transformation

    Chris Moore, Partner - EMEIA Advisory, EY

  • 9:45am
    Panel: Realising the potential of digital health by influencing behavioural change

    There is a huge amount of data now available to the healthcare industry. Now that this data is available, stakeholders are faced with the challenge of being able to produce knowledge that can better influence patient behaviour and ultimately bring disruption back to the public. How can this knowledge be combined with behavioural change that will ultimately improve patient’s health?

    Dr Priya Agrawal, Executive Director, MSD for Mothers

    Mark Duman, Non-Executive Director, Patient Information Forum (PiF) and Director, Intelesant

    Guy Yeoman, VP Patient Centricity, Astrazeneca

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 10:30am
    Morning break

    Section 2 – The adoption of digital health technologies

  • 11:00am
    Keynote case study: The Connecting Care programme

    Andy Kinnear, Director of Digital Transformation, NHS South, Central and West Commissioning Support Unit

  • 11:20am
    Digital health dialogue: Addressing the challenge of interoperability

    One of the biggest barriers to digital health being fully adopted is the lack of interoperability within the industry and existing IT infrastructures. A conversation between the FT chair and prominent digital health leaders will discuss in depth, the problems with interoperability when it comes to current healthcare practices and identify the most promising solutions to this industry-wide hurdle?

    Augustine Amusu, Head of IT Programmes, HCA Hospitals

    Sarah Haywood, Chief Executive Officer, MedCity

    Wilhelm Muehlhausen, Head of Innovation, ICON

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 12:00pm
    Keynote address: The realisation of digital health for a tech conglomerate

    Given their financing and resource availability, much has been said about big technology organisations entering and dominating the digital health space. Yet are their activities still based around simple market presence or do they now view this industry as a serious consumer market in which to do business?

    Dr Karl Pall, Director of Brand Solutions DACH (Division of Adult and Community Health), Google

    Section 3 – Creating a safe and secure healthcare environment

  • 12:20pm
    Digital health dialogue: Strengthening industry collaboration in order to overcome regulatory hurdles
    • Is there enough communication between healthcare stakeholders - from pharma to start-ups - when researching and developing new health technologies and data?
    • How can the industry generate collaboration when adhering to new policies such as the Falsified Medicines Directive?
    • The role of regulation and communication when ensuring there is a balance between product opportunity and product safety – for example, the increase in sophistication of digital pills

    Charles Lowe, Managing Director, Digital Health And Care Alliance (DHACA) and Immediate Past President, Telemedicine & eHealth Section, Royal Society of Medicine

    Pēteris Zilgalvis, Head of Unit, Health and Wellbeing, Directorate General Communications Networks, Content and Technology, European Commission

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 12:50pm
    Lunch
  • 2:10pm
    Matching the right patient to the right clinical trial

    Improving clinical trials and patient experiences by enhancing the feasibility, site selection and clinical research planning in digital health. Specific examples include the use of EMR and algorithmic patient identification.

    Tom O'Leary, Chief Information Officer, ICON

  • 2:25pm
    The cyber threat – how do we protect digital health technologies and their accessibility to data?
    • Is cyber, not data privacy, now the biggest security concern among patients?
    • Given the progress of digital health, when will cyber threats become a priority for regulators?
    • How can the healthcare industry learn from others before it?
    • Who should have access to medical records and data?
    • How will the development and increased usage of health and wellness wearables impact the concern over data security?

    Fabrice Naftalski, Head of Digital and Data Privacy Law Practice, EMEIA, EY

    Dr Scott Steedman, Director of Standards, BSI Group

    Dan Taylor, Programme Head of Cybersecurity, Health and Social Care Information Centre (HSCIC)

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

    Section 4 – Investing in disruption

  • 3:00pm
    Start-up spotlight session

    Disruptors still dominate the backbone of the newly-born digital health universe and while they range significantly in terms of application and purpose, they all play a crucial role in the future of healthcare delivery. Three 15-minute interviews, each involving a 10 minute opening pitch will showcase the latest apps, monitors, big data and medical devices that are gaining investment and consumer traction in health and wellness industries.

    3:00pm     Dr Ali Parsa, CEO, Babylon

    3:15pm     Dr Sophie Chung, CEO and Founder, Junomedical   

    3:30pm     Dr Sophie Bostock, Sleep Evangelist, Big Health

    3:45pm     Dr Matt Jameson Evans, Co-founder and Chief Medical Officer, Health Unlocked

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 4:00pm
    How does a digital health startup in the EU create pathways to market acceptance in the US and vice versa?

    Opportunities in segments such as telemedicine, remote monitoring and censoring, digital pills and remote data research are increasing around the world. More importantly they are bringing about discussions on how technologies and systems can be integrated and transported from one market to another. This panel of industry experts will assess the opportunities and challenges for expanding digital health innovations into market-wide products.

    Pablo Graiver, CEO, TrialReach

    Martin Kelly, Co-­founder and CEO, HealthXL

    Alexandra Pelletier, Presidential Innovation Fellow, The White House

    Unity Stoakes, Co-founder and President, StartUp Health

    Dr Jamie Wilson, Founder and CEO, HomeTouch

    Moderated by David Crow, Senior US Business Correspondent, Financial Times

  • 4:50pm
    Panel: Maximising ROI by moving to the next investment level in digital health

    R&D, innovations, better care delivery and presence in the market have been key decision points for digital health investors so far.However,with the value of digital health investments almost doubling around the world last year and with market projections forecasting that the industry could reach over £155 billion by 2020, investors will surely now shift their focus towards maximising their return on a shorter basis. What will this mean for incumbents and start-ups alike and is there now a more varied range of investment platforms?

    Richard Corbridge, Chief Information Officer, Health Service Executive Ireland and Chief Officer, eHealth Ireland

    Christoph Ruedig, Partner, Albion Ventures

    Adam Plich, Vice President, Head of Pricing & Market Access Europe, Teva Pharmaceuticals

    James Wise, Partner, Balderton Capital

    Moderated by Chris Moore, Partner - EMEIA Advisory, EY

  • 5:30pm
    Closing remarks from the chair

    David Crow, Senior US Business Correspondent, Financial Times

  • 5:35pm
    Drinks reception

Why attend?

  • Assess how patients are being empowered and further involved in the transformation of healthcare
  • Hear how collaborations between pharma and big tech are enriching the commercial viability of digital health
  • Meet and greet with the full array of industry stakeholders, from healthcare to technology, pharma to start-ups, regulation to government
  • Identify solutions in overcoming cyber security threats in digital health
  • Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare
fallback

Who attends?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Digital Health Summit Europe will be attended by:

  • Life science companies
  • Pharmaceutical and biotechnology companies 
  • Healthcare providers 
  • Multi-technology corporations 
  • Investment banks 
  • Medical device manufacturers 
  • Health insurers 
  • Health/big data companies 
  • Venture capitalists 
  • Health regulatory agencies 
  • Mobile app providers 
  • Mobile operators and service providers 
  • Technology consultancies 
  • Management consultancies 
  • Telemedicine companies 
  • Mobile technology manufacturers 
  • Digital health companies 
  • Data integrators/analytics/brokers 
  • Genomics/personalised medicine related companies 
  • Wireless-device manufacturers
fallback

Why Sponsor?

  • Gain access to senior decision makers across the full spectrum of the healthcare industry
  • Brand alignment with the FT and its unrivalled credibility
  • Demonstrate thought leadership around the current critical issues affecting the healthcare sector
  • Benefit from sustained international visibility through our advertising and marketing campaigns
fallback

Platinum Sponsor (2)

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and to government. The company specialises in the strategic development, management and analysis of programs that support clinical development.  ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life. 

ICON has built a reputation as an industry innovator and expert in transforming pharma R&D through strategic partnerships and alliances. The company’s expertise in managing and interpreting large clinical and real-world data sets has led to its selection by organisations involved in key transformative projects, including the 100,000 Genomes Project, the world’s largest genome sequencing project for cancer and rare diseases. ICON has also been chosen by the International Consortium for Health Outcomes Measurement (ICHOM) to advance value-based healthcare through the creation of the world’s first global healthcare outcomes benchmarking program. 

With headquarters in Dublin, Ireland, ICON currently operates from 88 locations in 37 countries and has approximately 12,600 employees. For further information please visit www.iconplc.com. Follow @iconplc on Twitter.

How EY’s Global Life Sciences Sector can help your business
Life sciences companies — from emerging start-ups to multinational enterprises — face new challenges in a rapidly changing health care ecosystem. Payers and regulators are increasing scrutiny and accelerating the transition to value and outcomes. Big data and patient-empowering technologies are driving new approaches and enabling transparency and consumerism. Players from other sectors are entering health care, making collaborations increasingly complex. These trends challenge every aspect of the life sciences business model, from R&D to marketing. Our Global Life Sciences Sector brings together a worldwide network — more than 7,000 sector-focused assurance, tax, transaction and advisory professionals — to anticipate trends, identify their implications and develop points of view on responding to critical issues. We can help you navigate your way forward and achieve success in the new ecosystem.

Supporting Partner (2)

MedTech Europe is an alliance of European medical technology industry associations. The Alliance was founded by EDMA, representing the European in vitro diagnostic industry, and Eucomed, representing the European medical devices industry. Other European medical technology associations are welcome to join the Alliance, established to represent the common policy interests of its members more effectively and efficiently.
Our mission is to make value-based, innovative medical technology available to more people, while supporting the transformation of healthcare systems onto a sustainable path. We promote a balanced policy environment that enables the medical technology industry to meet the growing healthcare needs and expectations of its stakeholders. In addition, we demonstrate the value of medical technology by encouraging our members to execute the industry’s 5-year strategy.

The Journal of mHealth is an international publication which brings the latest professional developments in mobile and digital health technologies to healthcare and industry professionals around the world. Featuring, the Latest Industry News, Articles, Research, Industry Whitepapers, Market Reports, and Service Reviews.
The Journal is widely read by healthcare and industry professionals from both North American and European markets, where the publication is a leading resource for anyone with an interest in connected health technologies, applications, devices, and services.

Venue

etc.venues St Paul's
200 Aldersgate
London EC1A 4HD

United Kingdom

Tel: +44 (0) 20 3011 0830

fallback

Accommodation

For accommodation near to the event venue please click here

fallback

Digital Health Summit 2016 Highlights

To view the full selection of photographs from the Digital Health Summit Europe 2016 please click here

FT Digital Health Summit Europe 2016   Flickr   Photo Sharing

fallback

Contact Us

Charlie Hayward
Speaking Opportunities
Financial Times
Gigs Thoukidides
Sponsorship Opportunities
Financial Times
Aneliese Hirst
Media Partner And Press Enquiries
Financial Times
Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times

2015's FT Digital Health Summit Europe

"There are still more questions than answers on digital health, which makes this summit highly relevant"
Philipp Gutzwiller, Global Head of Healthcare, Lloyds Bank Healthcare

"Good topics on the cutting edge, learned a lot, will come again"
Emer Brizzolara, Strategy Director, Ogilvy Healthworld

"Excellent overview, leader’s forum and regulatory sessions very good!"
Chris Hunt, Director, Microarray

"Diverse opinions contributed to an informed and engaging debate"
John Britton, Senior Director, ResMed

"Really good, well thought out agenda, I really learnt a lot"
Anonymous

"Much condensed into a single day. Heard a number of key points that I had not heard elsewhere. The highlight was the innovation panel"
Anonymous

"Excellent calibre of speakers from a range of industries and functions"
Anonymous

"An excellent summit, good speakers, relevant topics and lively discussion"
Anonymous

"Expert professionals thinking about subject pertinent topics in pleasant environment. Will come again"
Anonymous

Further details of the 2015 FT Digital Health Summit Europe can be found here >>

fallback